

## **AusCann appoints experienced global pharmaceutical executive as new CEO**

**25 February 2019** – The Board of leading medicinal cannabis company **AusCann Group Holdings Limited** (ASX:AC8) ('AusCann' or 'the Company') is pleased to announce the appointment of global pharmaceutical business executive, Mr. Ido Kanyon, as Chief Executive Officer (CEO), commencing 22<sup>nd</sup> May 2019.

Mr. Kanyon brings more than 15 years' senior executive experience in the pharmaceutical industry most recently at Teva Pharmaceutical Industries ('Teva'), the world's largest generic pharmaceutical company which also specialized in the development and commercialization of active pharmaceutical ingredients and specialty proprietary medicines. Teva is listed on the NYSE with FY17 revenues of over US\$22 billion.

Before taking the leadership of AusCann, Mr. Kanyon was the Global Head of Specialty Pipeline, Global Marketing and Portfolio at Teva headquarters in the U.S. where he was responsible for the company's Specialty Medicine multi-billion specialty pipeline portfolio with the goal of maximizing the value of the company's R&D investment on innovative medicines. Formerly, he served as a global commercial senior director for Teva's Respiratory business, driving commercial growth for the firm's Respiratory franchise. Before his commercial tenure at Teva, his expertise in operational excellence across multiple R&D and Manufacturing pharmaceutical technologies allowed him to design and implement best-in-class industry standards to transform Teva's operational performance in sites across North America, Europe, Asia Pacific and the Middle East. Previously, Mr. Kanyon held several Quality Assurance and Regulatory Affairs leadership roles at Teva.

Mr. Kanyon began his career working in agriculture research and Agritech R&D field. He then joined a publicly traded Medical Device startup covering R&D, Intellectual property and business development. He holds a Bachelor of Science, Agriculture (botany), from The Hebrew University of Jerusalem and an MBA from IE Business School in Spain.

AusCann Chairman, Dr Mal Washer, commented: "Our extensive executive search generated an impressive field of candidates and Ido stood out for his leadership acumen and track record of commercial achievements throughout his career.

"Ido is very highly regarded in the pharmaceutical industry and having worked both for startups and for one of the largest pharmaceutical firms worldwide, he understands AusCann's start-up origins and where the firm is headed. We are confident that his experience, energy and drive will successfully lead AusCann into its next phase of growth as a pharmaceutical development, sales and marketing business.

"We are extremely pleased to have attracted such a high calibre executive and welcome Ido to his new role."

Mr. Ido Kanyon added: "I am absolutely delighted to be appointed as AusCann's CEO during this exciting time. Medicinal cannabis will have an ever-increasing presence in healthcare as a credible treatment for chronic pain and additional indications with unmet medical needs. I believe there is a unique opportunity to place patients, physicians and caregivers at the center of our mission. I am excited by AusCann's commitment to deliver with the highest standards of quality, innovation and trust. I would like to thank the Board for their

For personal use only

appointment and look forward to working with the incredibly talented team already in place. AusCann has everything in place to achieve a leading position in the rapidly growing field of medical cannabis, and to capitalize on the excellent work done under the leadership of Ms. Elaine Darby and interim CEO Dr. Paul MacLeman. We have a promising future ahead of us and we will make sure to deliver sustain value for our investors, customers and employees.”

With the CEO appointment, Interim CEO, Dr. Paul MacLeman, will step back into his role as an Executive Director when Mr. Kanyon commences with the business on 22<sup>nd</sup> May 2019.

In accordance with ASX Listing Rule 3.16.4, the key terms of Mr. Kanyon’s employment agreement are set out in the attached summary.

**ENDS**

**For more information, please contact:**

**For Investment Enquiries**

Quentin Megson  
Chief Operating and Financial Officer  
info@auscann.com.au  
+61 8 9561 8834

**For Media Enquiries**

Elodie Castagna  
FTI Consulting  
elodie.castagna@fticonsulting.com  
+61 8 9321 8533

For personal use only

**Attachment 1**  
**Mr. Ido Kanyon – Key Terms and Conditions of Employment**

---

<b>Commencement Date</b>	22 <sup>nd</sup> May 2019
<b>Term</b>	Appointment on an-going basis subject to termination by either party (see termination and notice below)
<b>Fixed Remuneration</b>	\$420,000 per annum base salary
<b>Superannuation</b>	Statutory superannuation payments of \$20,531.40 or other as mandated
<b>Short Term Incentives</b>	Short Term Incentives of up to 33% of base salary subject to achieving key performance indicators to be defined by the Board
<b>Long Term Incentives</b>	The Employee will be permitted to participate in the Employer's Share and Option Plan
<b>Termination and Notice</b>	The Company or the CEO may terminate the agreement by providing 6 months' notice. The Company may elect, at its discretion, to make payment in lieu.

---

**ABOUT AUSCANN**

AusCann Group Holdings Limited (ASX:AC8) is an Australian-based pharmaceutical company that aims to produce high quality, economical, and clinically validated cannabinoid medicines. AusCann is bringing together leading expertise and operations across all aspects of the medical cannabis value chain, beginning with cultivation and production, through to manufacture and distribution of products. Through partnerships with industry experts, existing leading market participants and doctors, AusCann is building operations and educating the medical community about the benefits of cannabinoid medicines. Incorporated in 2014, AusCann holds the full set of necessary licenses to grow and manufacture cannabinoid medicines in Australia. The company is initially targeting medications for neuropathic and chronic pain in Australia and Chile, whilst exploring global export opportunities.

For personal use only